Recent Advances in Lung Cancer

April 5, 2008

Hershey, PA

Overview

Recent Advances in Lung Cancer

Program Director

Chandra P. Belani, MD, Miriam Beckner Professor of Medicine, Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Deputy Director, Penn State Cancer Institute, Hershey, PA

Target Audience

This symposium is directed primarily to medical oncologists, radiation oncologists, surgical oncologists, pharmacists, researchers and registered oncology nurses interested in new developments for treatment of lung cancer. No specific skill or knowledge other than a basic training in oncology is required for successful participation in this activity. Fellows, nurses are also invited to attend.

Statement of Need/Program Overview

Recent advances in lung cancer is intended to provide comprehensive updates on biology, diagnosis, and management of lung cancer. Paradigm shift in the treatment options for nonsmall-cell lung cancer and small-cell lung cancer will be discussed. This meeting will facilitate interaction among oncologists and researchers interested in development of novel therapeutics for treatment of lung cancer. This symposium will present data of most promising emerging agents currently in development for the treatment of lung cancer. The format will include didactic lectures from known thought leaders, question and answer session, and ample opportunity for participant interaction with faculty. In-depth discussion of antiangiogenic agents, inhibitors of EGFR pathways, and drugs that target multiple signaling pathways will be given significant focus. The role of proteasome inhibitors, HDAC inhibitors and novel taxanes in the treatment of lung cancer will be discussed. Emerging data from ongoing clinical research will be presented.

Educational Objectives

After completing this activity, the participant should be better able to:

• Define the current status of targeted therapy and radiation therapy in the treatment of localized and advance lung cancer

• Outline the clinical data supporting the use of EGFR and VEGFR inhibitors including the safety profile and efficacy in the treatment of lung cancer

• Describe novel therapeutic agents such as proteasome inhibitors, HGAC inhibitors and novel taxanes that potentially improve upon standard chemotherapeutics

• Specify the impact of multi-targeted kinase inhibitors in the management of lung cancer

• Explain the ERCC and RRMI expression on treatment selection of patients with lung cancer

• Describe the role of vaccines for lung cancer

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and International Lung Cancer Network. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Postgraduate Institute for Medicine designates this educational activity for a maximum of 5.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 5.0 contact hours (0.5 CEUs) of the Accreditation Council for Pharmacy Education. 

(Universal Program Number – 809-999-07-163-L01-P)

Nursing Accreditation Statements

CNA/ANCC

This educational activity for 5.0 contact hours is provided by Postgraduate Institute for Medicine (PIM).

PIM is an approved provider of continuing nursing education by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

California Board of Registered Nursing

Postgraduate Institute for Medicine is approved by the California Board of Registered Nursing, Provider Number 13485 for 6.0 contact hours.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be mailed to you within three weeks.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

.Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Roberta Granny prior to the live event at 717-531-1078.